Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

AbbVie

- PMLiVE

AbbVie shares positive results for Rinvoq in head-to-head atopic dermatitis study

An estimated 10% of adults and 24.6% of adolescents are affected by the inflammatory skin condition

- PMLiVE

AbbVie’s oral therapy Aquipta recommended by NICE for migraine prevention in adults

Approximately 170,000 patients in England are expected to benefit from the agency’s decision

- PMLiVE

AbbVie to expand inflammatory and autoimmune disease portfolio with $212.5m Landos acquisition

The deal will advance the clinical development of NX-13 for patients living with ulcerative colitis and Crohn’s disease

- PMLiVE

AbbVie’s Elahere granted full FDA approval for previously-treated ovarian cancer

The company recently gained access to the therapy through its $10.1bn acquisition of ImmunoGen

- PMLiVE

AbbVie and Parvus Therapeutics collaborate to develop treatments for inflammatory bowel disease

Both companies will utilise Parvus’ Navacim Treg immune tolerisation platform technology

- PMLiVE

Dermavant reports positive late-stage results for Vtama cream in atopic dermatitis

The inflammatory skin disease affects up to 10% of adults and 20% of children worldwide

- PMLiVE

Eli Lilly shares positive late-stage results for lebrikizumab in atopic dermatitis

The study evaluated lebrikizumab in patients with moderate-to-severe AD and darker skin tones

- PMLiVE

Sanofi shares promising results for amlitelimab in moderate-to-severe atopic dermatitis

Amlitelimab could potentially offer treatment for a range of other immune-mediated diseases and inflammatory disorders

- PMLiVE

AbbVie gains rights to OSE’s chronic inflammation therapy in deal worth $713m

The company will gain an exclusive global license to develop, manufacture and commercialise OSE-230

- PMLiVE

AbbVie and Tentarix partner to develop oncology and immunology biologics

The collaboration will use Tentarix's proprietary platform to develop biologics against two targets

- PMLiVE

AbbVie’s Produodopa rolled out by NHS England for advanced Parkinson’s patients

The roll out follows NICE’s recommendation of the treatment in October 2023

- PMLiVE

Almirall and CRG partner to advance therapeutic approaches for atopic dermatitis

The inflammatory skin disease currently affects an estimated 4.4% of adults in the EU

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links